麻痺(Paralysis)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Paralysis Overview 6
Therapeutics Development 7
Pipeline Products for Paralysis – Overview 7
Pipeline Products for Paralysis – Comparative Analysis 8
Paralysis – Therapeutics under Development by Companies 9
Paralysis – Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Paralysis – Products under Development by Companies 13
Paralysis – Companies Involved in Therapeutics Development 14
Asahi Kasei Pharma Corp. 14
Immunome Inc. 15
Marathon Pharmaceuticals, LLC 16
Neuralstem, Inc. 17
Paralysis – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
BNZ-1321 – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
elcatonin – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
flunarizine hydrochloride – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody Conjugates for Paralysis – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NSI-566 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
REM-1086 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Paralysis – Recent Pipeline Updates 35
Paralysis – Dormant Projects 42
Paralysis – Discontinued Products 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45